Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
8 evidence topics · 19 sources
Summary
- No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
- Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
- Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
- Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
- Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
- Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
- Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
- Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.
No curative therapy and restricted access to combination treatment
“No currently available therapies for NPC are curative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improving the accessibility and affordability of novel therapies is crucial for enhancing patient outcomes in NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No therapy shown to reduce mortality before the LEMBAZ approval
Sponsor and investigator statements on limited options in infantile-onset disease
Evidence gaps for arimoclomol and levacetylleucine identified by the ACMG
“Neither trial addressed nonneurological manifestations, such as liver disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are no published studies of outcomes or safety addressing coadministration of arimoclomol and levacetylleucine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Available data for treatment of NPC with arimoclomol or levacetylleucine beyond 5 years are extremely limited; long-term outcomes are not known.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence gaps identified in a state Medicaid drug class review
Limited access to disease-modifying therapy in the Australian standard of care
“Disease‐modifying treatment options for NP‐C are limited (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For many individuals, clinical trial participation may be the only way to access disease‐modifying treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With no cure and limited access to disease‐modifying therapy, optimal management in Australia comprises symptomatic treatment of clinical manifestations and ongoing monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote